Finerenone in Type 1 Diabetes and Chronic Kidney Disease

20262 citationsJournal Article

Authors

Hiddo J.L. Heerspink · University Medical Center Groningen

Andreas L. Birkenfeld · Deutsches Diabetes-Zentrum e.V.

David Z.I. Cherney · University Health Network

Helen M Colhoun · Edinburgh Cancer Research

Per-Henrik Groop · University of Helsinki

Linong Ji · Peking University

Niels Jongs

Abstract

In adults with type 1 diabetes and CKD, finerenone resulted in a significantly greater decrease in the urinary albumin-to-creatinine ratio than placebo. (Funded by Bayer; FINE-ONE ClinicalTrials.gov number, NCT05901831.).

Topics & Keywords

Hormonal Regulation and Hypertension Diabetes and associated disorders Adrenal Hormones and Disorders

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 394, Issue 10, pp. 947-957

DOI: 10.1056/nejmoa2512854

Field-Weighted Citation Impact: 59.44